lifestyle.newsblaze.com

Author: Biodexa Pharmaceuticals PLC

Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies

April 2, 2026
Preliminary Results for the Year Ended 31 December 2025

March 30, 2026
Preliminary Results for the Year Ended 31 December 2025

March 26, 2026
Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group

March 23, 2026
ADR Ratio Change

March 18, 2026
Biodexa Announces Support for Life’s a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients

March 9, 2026
Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer

February 19, 2026
Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent Phase 1 ready Molecular Glue for GIST

February 10, 2026